Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia

Alexander Claviez; Cornelia Eckert; Karl Seeger; André Schrauder; Martin Schrappe; Günter Henze; Arend von Stackelberg

Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia

Haematologica. 2006 Feb;91(2):272-3.

Authors

Alexander Claviez, Cornelia Eckert, Karl Seeger, André Schrauder, Martin Schrappe, Günter Henze, Arend von Stackelberg

PMID: 16461321

Abstract

We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load. Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Child
Child, Preschool
Female
Hematopoietic Stem Cell Transplantation
Humans
Male
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
Rituximab
Salvage Therapy / methods*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Rituximab